Lei Xu

Lei Xu

Auto-generated profile, based on publicly available information

Lei Xu

Department of Gastroenterology Nanjing Drum Tower Hospital Affiliated Hospital of Medical School Nanjing University Nanjing Jiangsu China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2024 in Cancer Research
Verified
Journal Article
Closed access
YPYani Pan
Yani Pan
YZYue Zhou
Yue Zhou
YSYonghua Shen
Yonghua Shen
LXLei Xu
Lei Xu
HLHongwen Liu
Hongwen Liu
LWLei Wang
Lei Wang
Cholangiocarcinoma (CCA) displays enhanced glycolysis, pivotal for fulfilling the heightened energy demands intrinsic to its malignant progression. Recent research has indicated that endogenous glycogen rather than exogenous glucose acts as the major carbon source for glycolysis, highlighting the need to better understand the regulation of glycogen homeostasis in CCA. Here, through comprehensive integrative analysis, we identified that glycogen phosphorylase brain form (PYGB), the main enzyme involved in glycogen homeostasis, was markedly upregulated in CCA tissues, serving as an independent prognostic indicator for human patients with CCA. Moreover, elevated PYGB expression potentiated cholangiocarcinogenesis and augmented CCA cell proliferation in both organoid and xenograft models. Hypoxia stimulated PYGB activity in a phosphoglycerate kinase 1–dependent manner, leading to glycogenolysis and the subsequent release of glucose-6-phosphate (G6P) and thereby facilitating aerobic glycolysis. Notably, a virtual screening pinpointed the β-blocker carvedilol as a potent pharmacologic inhibitor of PYGB that could attenuate CCA progression. Collectively, these findings position PYGB as a promising prognostic biomarker and therapeutic target for CCA. Significance: Cholangiocarcinoma cells exhibit high glycogen phosphorylase activity under hypoxic conditions that mediates metabolic reprograming to promote glycolysis and support tumor development.

4 March 2026 in Research
Verified
Journal Article
Open access
XTXinyu Tong
Xinyu Tong
HCHaoyu Chao
Haoyu Chao
CZChenlu Zhang
Chenlu Zhang
ZLZhuojin Li
Zhuojin Li
QHQuan Han
Quan Han
Dijun ChenDijun Chen
Dijun Chen
Liver metastasis remains a major challenge in cancer treatment, yet its cellular and molecular landscape remains poorly defined at the pan-cancer level. Here, we construct a single-cell transcriptomic atlas of liver metastases across multiple cancer types by analyzing 100 single-cell RNA sequencing samples, profiling over 460,000 cells, and identifying 121 distinct cellular subtypes. We define 4 representative cellular programs (CPs) associated with liver metastasis, revealing how cellular composition and intercellular interactions within the tumor microenvironment drive metastatic progression and immune modulation. These CPs recapitulate a dynamic transition from immunoactive states, marked by natural-killer-cell-mediated immune surveillance and macrophage-driven angiogenesis, to immunosuppressive environments dominated by regulatory T cell infiltration and immune exclusion. The shift is marked by progressive alterations in immune infiltration, stromal remodeling, and tumor-intrinsic adaptations, elucidating key mechanisms of immune evasion and metastatic niche formation. Our study provides a high-resolution framework for understanding the heterogeneity and evolution of liver metastasis and highlights the potential of CP-based stratification to inform therapeutic strategies targeting the metastatic tumor microenvironment.

17 June 2026
Verified
Other
Open access
YPYani Pan
Yani Pan
YZYue Zhou
Yue Zhou
YSYonghua Shen
Yonghua Shen
LXLei Xu
Lei Xu
HLHongwen Liu
Hongwen Liu
LWLei Wang
Lei Wang
Screening of Carvedilol as a CCA therapeutic drug.

17 June 2026
Verified
Other
Open access
YPYani Pan
Yani Pan
YZYue Zhou
Yue Zhou
YSYonghua Shen
Yonghua Shen
LXLei Xu
Lei Xu
HLHongwen Liu
Hongwen Liu
LWLei Wang
Lei Wang
Hypoxia-induced enhancement of PYGB enzyme activity is dependent on the kinase function of PGK1.

15 November 2024
Verified
Other
Open access
PDF file
YPYani Pan
Yani Pan
YZYue Zhou
Yue Zhou
YSYonghua Shen
Yonghua Shen
LXLei Xu
Lei Xu
HLHongwen Liu
Hongwen Liu
LWLei Wang
Lei Wang
Carvedilol suppressed the malignancy of CCA in vivo.

15 November 2024
Verified
Other
Open access
YPYani Pan
Yani Pan
YZYue Zhou
Yue Zhou
YSYonghua Shen
Yonghua Shen
LXLei Xu
Lei Xu
HLHongwen Liu
Hongwen Liu
LWLei Wang
Lei Wang
PYGB is highly expressed in malignancy/cholangiocytes and is associated with glycogenolysis.